Renaissance Technologies LLC Decreases Position in Kura Oncology, Inc. (NASDAQ:KURA)

Renaissance Technologies LLC decreased its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 49.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,200 shares of the company’s stock after selling 119,000 shares during the quarter. Renaissance Technologies LLC owned about 0.16% of Kura Oncology worth $2,496,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KURA. BVF Inc. IL raised its stake in Kura Oncology by 9.5% in the fourth quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock valued at $106,027,000 after buying an additional 642,245 shares during the last quarter. Vanguard Group Inc. grew its position in Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after purchasing an additional 28,212 shares during the last quarter. Avoro Capital Advisors LLC increased its stake in Kura Oncology by 29.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after purchasing an additional 870,000 shares in the last quarter. Artal Group S.A. raised its holdings in shares of Kura Oncology by 8.6% in the first quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock worth $40,951,000 after buying an additional 151,828 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Kura Oncology by 50.1% during the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after buying an additional 577,732 shares during the period.

Kura Oncology Trading Down 1.7 %

KURA stock opened at $19.21 on Wednesday. Kura Oncology, Inc. has a 12-month low of $7.41 and a 12-month high of $24.17. The business’s 50-day moving average is $20.00 and its 200 day moving average is $20.49. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -8.85 and a beta of 0.84.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.04. The business’s revenue was up .0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.53) EPS. On average, sell-side analysts anticipate that Kura Oncology, Inc. will post -2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

KURA has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a research note on Monday, August 12th. JMP Securities reiterated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a research report on Monday, August 12th. Wedbush reissued an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research report on Friday, August 9th. Stifel Nicolaus cut their price objective on shares of Kura Oncology from $28.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Finally, StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat, Kura Oncology has a consensus rating of “Moderate Buy” and an average price target of $30.60.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.